Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 1 B, 2005, Pages 471-475

  Ostoros, Gyula ^a,d   Szondy, Klára ^b   Gergely Farnos, Erzsébet ^a   Magyar, Pál ^b   Strausz, János ^c   Ferenczi, Eniko ^c   Kovács, Gábor ^a  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Institute of Physiotherapy   (Hungary)

^d National Institute of Pulmonology   (Hungary)

Author keywords

Cisplatin; Gemcitabine; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 16344374079     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ottó Sz, Kásler M: Mortality and incidence of cancer in Hungary. Hungarian Oncology 46: 111-116, 2002.
2. Ginsberg RJ, Vokes EE and Raben A: Non small cell lung cancer. In: DeVita VT, Hellmann S, Rosenberg SA. Cancer: Principles and Practice of Oncology. Philadelphia PA, Lippincott-Raven, 1997, 858-865.
3. Non-small cell lung cancer collaborative group: Chemotherapy in NSCLC: A meta analysis using updated data on individual patients from 52 randomized trials. Br Med J 311: 899-909, 1995.
4. Crino L: Combining platinum containing treatment in NSCLC. Lung Cancer 38: 51-52, 2002.
5. Pirker R: Two versus three-drug combination in the chemotherapy of advanced non-small-cell lung cancer. Lung Cancer 38: 53-55, 2002.
6. Schiller JH, Harrington D, Sandler A et al: ECOG 1594: A randomized Phase III trial of 4 chemotherapy regimens in advanced NSCLC. N Eng J Med 346: 92-98, 2002.
7. Le Chevalier T: Single agent activity of gemcitabine in advanced non- small cell lung cancer. Semin Oncol 23: 36-42, 1996.
8. Shepherd F: Phase II trials of single agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview: Anti cancer Drugs 6: 19-25, 1995.
9. Sandler A, Nemunaitis J, Dehnam et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin in patients with locally advanced or metastatic lung cancer. J Clin Oncol 18: 122-130, 2000.
10. Castellano D, Lianes P, Paz-Ares L et al: A phase II study of novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small cell lung cancer. Ann Oncol 9: 457-459, 1998.
11. Socinski MA: Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC. Lung Cancer 41: 93-94, 2003.
12. Cardenal F, Lopez-Cabreriza MP, Anton A et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17: 12-18, 1999.
13. Crino L, Scagliotti GV Ricci et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530, 1999.
14. Manegold C: Treatment of elderly patients with non-small-cell lung cancer. Oncology 15: 46-51, 2001.
15. Shepherd FA, Dancey J, Ramlou R et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
16. Georgoulias VA: Second-line chemotherapy in relapsing or refractory patients with non-small-cell lung cancer. Lung Cancer 38: 61-66, 2002.
17. Van Zandwijk N: Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N(2) NSCLC: A phase II study EORTC Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 18: 2658-2664, 2000.
18. DeMarinis F: Gemcitabine, paclitaxel and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA (N2) NSCLC. Cancer 98: 1707-1715, 2003.